Hong Kong stocks surged again, with China Biopharmaceuticals (01177.HK) rising by over 6%. Zong Aitini obtained groundbreaking CDE qualification for its treatment, and its performance in the first half of the year exceeded market expectations.
According to the Wise Financial App, China Biotech (01177.HK) rose by more than 6% again, as of the time of writing, it increased by 5.44% to 8.14 Hong Kong dollars, with a trading volume of 1.077 billion Hong Kong dollars.
Latest
